A new interview with Vikram Punia, President and Founder of the Pharmasyntez Group of Companies

Topics discussed:

• challenges, successes and failures of this year

• changes in manufacturing

• findings and developments

• drug prices 

• the global pharmaceutical market conjuncture

and why Russia needs domestic companies of a “Big Pharma” level.

Timecodes:

0:30 Most difficult moments for the company in 2020

4:40 Promising drugs

8:13 The Remdesivir case

11:26 Clinical studies carried out by Pharmasyntez and their outcomes 

13:30 Сriticism of Remdesivir in the press

15:17 Degree of demand for the drug 

17:04 Pricing

20:33 Manufacturing and compulsory licensing

25:35 Vaccines

27:51 Plant reconfiguring for vaccine production: would the costs be justified?

32:36 Does “Russian Pharma” challenge “Big Pharma”?

35:32 Import substitution and innovations

42:37 Russia’s need in large domestic pharmaceutical companies